Zomedica FY 2025 net loss widened 74% to USD 81.86 million on revenue up 17% to USD 32.03 million

Reuters03-17

Zomedica FY 2025 net loss widened 74% to USD 81.86 million on revenue up 17% to USD 32.03 million

Zomedica published its annual report on Form 10-K for FY 2025. Revenue rose 17% to USD 32.03 million, driven mainly by contract manufacturing and engineering revenue, growth in PulseVet consumables, growth in TRUFORMA products including new assay launches, and initial sales of VETIGEL. Net loss widened 74% to USD 81.86 million, primarily due to impairment expense of USD 55.83 million tied to a sharp decline in market capitalization following the company’s delisting from NYSE American. Cash used in operating activities fell 25% to USD 17.65 million, reflecting lower operating expenses excluding non-cash charges. Cash and cash equivalents ended the year at USD 9.02 million, and management said existing cash is sufficient to fund expected short-term needs and long-term operational requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zomedica Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-028450), on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620499114?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 04:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620499114","market":"us","top_or_hot":-1,"title":"Zomedica FY 2025 net loss widened 74% to USD 81.86 million on revenue up 17% to USD 32.03 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zomedica FY 2025 net loss widened 74% to USD 81.86 million on revenue up 17% to USD 32.03 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zomedica published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for FY 2025. Revenue rose 17% to USD 32.03 million, driven mainly by contract manufacturing and engineering revenue, growth in PulseVet consumables, growth in TRUFORMA products including new assay launches, and initial sales of VETIGEL. Net loss widened 74% to USD 81.86 million, primarily due to impairment expense of USD 55.83 million tied to a sharp decline in market capitalization following the company’s delisting from NYSE American. Cash used in operating activities fell 25% to USD 17.65 million, reflecting lower operating expenses excluding non-cash charges. Cash and cash equivalents ended the year at USD 9.02 million, and management said existing cash is sufficient to fund expected short-term needs and long-term operational requirements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ZOMDF\">Zomedica Corp.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-028450), on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zomedica FY 2025 net loss widened 74% to USD 81.86 million on revenue up 17% to USD 32.03 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZomedica FY 2025 net loss widened 74% to USD 81.86 million on revenue up 17% to USD 32.03 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-17 04:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zomedica FY 2025 net loss widened 74% to USD 81.86 million on revenue up 17% to USD 32.03 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zomedica published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for FY 2025. Revenue rose 17% to USD 32.03 million, driven mainly by contract manufacturing and engineering revenue, growth in PulseVet consumables, growth in TRUFORMA products including new assay launches, and initial sales of VETIGEL. Net loss widened 74% to USD 81.86 million, primarily due to impairment expense of USD 55.83 million tied to a sharp decline in market capitalization following the company’s delisting from NYSE American. Cash used in operating activities fell 25% to USD 17.65 million, reflecting lower operating expenses excluding non-cash charges. Cash and cash equivalents ended the year at USD 9.02 million, and management said existing cash is sufficient to fund expected short-term needs and long-term operational requirements.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ZOMDF\">Zomedica Corp.</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-028450), on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZOMDF","symbol_name":"Zomedica Corp.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL4zvQNH:1","article_id":"2620499114","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620499114","pubTimestamp":1773691803,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zomedica published its annual report on Form 10-K for FY 2025. Revenue rose 17% to USD 32.03 million, driven mainly by contract manufacturing and engineering revenue, growth in PulseVet consumables, growth in TRUFORMA products including new assay launches, and initial sales of VETIGEL. Net loss widened 74% to USD 81.86 million, primarily due to impairment expense of USD 55.83 million tied to a sharp decline in market capitalization following the company’s delisting from NYSE American. Cash used in operating activities fell 25% to USD 17.65 million, reflecting lower operating expenses excluding non-cash charges. Cash and cash equivalents ended the year at USD 9.02 million, and management said existing cash is sufficient to fund expected short-term needs and long-term operational requirements.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZOMDF":"Zomedica Corp.","BK4082":"医疗保健设备"},"translate_title":"Zomedica 2025财年净亏损扩大74%至8186万美元，收入增长17%至3203万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZOMDF":0.9},"content_text":"Zomedica FY 2025 net loss widened 74% to USD 81.86 million on revenue up 17% to USD 32.03 million\n    \n\n        Zomedica published its annual report on Form 10-K for FY 2025. Revenue rose 17% to USD 32.03 million, driven mainly by contract manufacturing and engineering revenue, growth in PulseVet consumables, growth in TRUFORMA products including new assay launches, and initial sales of VETIGEL. Net loss widened 74% to USD 81.86 million, primarily due to impairment expense of USD 55.83 million tied to a sharp decline in market capitalization following the company’s delisting from NYSE American. Cash used in operating activities fell 25% to USD 17.65 million, reflecting lower operating expenses excluding non-cash charges. Cash and cash equivalents ended the year at USD 9.02 million, and management said existing cash is sufficient to fund expected short-term needs and long-term operational requirements.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zomedica Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-028450), on March 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620499114","isCrawlerRequest":true}